https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-11-16 / Int. J. Oncol. 2012 Mar;40(3):840-502011-11-16 00:00:002021-11-15 16:57:44Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-10-04 / Int. J. Oncol. 2012 Jan;40(1):287-98
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-10-04 / Int. J. Oncol. 2012 Jan;40(1):287-982011-10-04 00:00:002021-11-15 16:58:12Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-05-09 / Int. J. Oncol. 2011 Aug;39(2):493-504
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-05-09 / Int. J. Oncol. 2011 Aug;39(2):493-5042011-05-09 00:00:002021-11-15 16:58:35Important role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-03-17 / Int. J. Oncol. 2011 Jun;38(6):1719-29
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-03-17 / Int. J. Oncol. 2011 Jun;38(6):1719-292011-03-17 00:00:002021-11-15 16:59:03Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-12-18 / Vaccine 2011 Feb;29(6):1185-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-12-18 / Vaccine 2011 Feb;29(6):1185-932010-12-18 00:00:002021-11-15 16:59:23Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-12-01 / Int. J. Oncol. 2010 Dec;37(6):1439-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-12-01 / Int. J. Oncol. 2010 Dec;37(6):1439-522010-12-01 00:00:002021-11-15 16:59:47Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Int. J. Oncol. 2010 Nov;37(5):1203-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Int. J. Oncol. 2010 Nov;37(5):1203-172010-11-01 00:00:002021-11-15 17:00:11Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-13 / Vaccine 2010 Oct;28(42):6891-900
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-13 / Vaccine 2010 Oct;28(42):6891-9002010-08-13 00:00:002021-11-15 17:00:34The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-04-01 / Pediatr Blood Cancer 2010 Apr;54(4):519-25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-04-01 / Pediatr Blood Cancer 2010 Apr;54(4):519-252010-04-01 00:00:002021-11-15 14:45:11Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-27 / J. Immunol. Methods 2010 Jan;352(1-2):169-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-27 / J. Immunol. Methods 2010 Jan;352(1-2):169-732009-10-27 00:00:002021-11-15 14:45:35Technical advancement in regulatory T cell isolation and characterization using CD127 expression in patients with malignant glioma treated with autologous dendritic cell vaccination